A study to evaluate post COVID-19 lung damage.

Not yet recruiting

• Conditions: Coronavirus as the cause of diseases classified elsewhere,

• Registration Number: CTRI/2020/11/029437
• Lead Sponsor: Medanta Institute of Education and Research

Brief Summary

This is a retrospective de-identified observational study to monitor the clinical and radiological course in patients with moderate or severe COVID-19 interstitial pneumonia and to study the changes in Computed Tomography findings after four weeks. Patients confirmed with COVID-19, admitted to Medanta-The Medicity and patients with moderate or severe COVID 19 pneumonia, admitted to ward or ICU will be included in the study.

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2020-11-26
• Study Start: 2020-12-15

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• Patients confirmed with COVID-19, admitted to Medanta-The Medicity, Gurgaon, India.
• Patients with moderate or severe COVID 19 pneumonia, admitted to ward or ICU.

Exclusion Criteria

• Age <18 years 2.
• Patients with mild COVID 19 3.
• Pregnant female 4.
• Patients with history of COVID-19 Interstitial Pneumonia treatment.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
High-resolution computed tomography (HRCT) features of COVID 19 at presentation and 12 weeks later	High-resolution computed tomography (HRCT) features of COVID 19 at presentation and 12 weeks later

Secondary Outcome Measures

Name	Time	Method
Effect of therapy used	Role of anti-fibrotic medications

Trial Locations

Locations (1)

Medanta-The Medicity; 🇮🇳 Gurgaon, HARYANA, India

Medanta-The Medicity

🇮🇳Gurgaon, HARYANA, India

Dr Bornali Datta

Principal investigator

9818462626

bornalidatta@googlemail.com